Quick Answer
AYTU BIOPHARMA, INC reported Total Revenue of $66.38 million for fiscal year 2025.
AYTU BIOPHARMA, INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $66.38M +1.8% |
$65.18M -39.3% |
$107.40M +11.1% |
$96.67M +47.3% |
$65.63M +137.5% |
$27.63M +277.5% |
| Revenue (ASC 606) | $66.38M +1.8% |
$65.18M -39.3% |
$107.40M +11.1% |
$96.67M +47.3% |
$65.63M +137.5% |
$27.63M |
| Net Income | -$13.56M +14.4% |
-$15.84M +7.1% |
-$17.05M +84.3% |
-$108.78M -86.6% |
-$58.29M -327.9% |
-$13.62M +49.8% |
| Diluted EPS | — | — | -$5.11 +93.1% |
-$74.01 -2026.7% |
-$3.48 | — |
| Total Assets | $124.18M +5.2% |
$118.09M -13.5% |
$136.46M -0.8% |
$137.62M -48.2% |
$265.67M +73.3% |
$153.29M +341.5% |
| Cash and Equivalents | $30.95M +54.7% |
$20.01M -13.0% |
$22.98M +18.7% |
$19.36M -61.0% |
$49.65M +3.3% |
$48.08M +335.4% |
| Long-Term Debt | — | $10.88M -26.1% |
$14.71M | — | — | — |
| Stockholders Equity | $18.97M -31.6% |
$27.72M -29.6% |
$39.36M -11.2% |
$44.31M -67.8% |
$137.57M +44.8% |
$95.02M +1240.5% |
| R&D Expense | $1.33M -52.1% |
$2.77M -32.4% |
$4.09M -67.7% |
$12.66M +125.2% |
$5.62M +226.5% |
$1.72M +192.3% |
| Operating Income | -$7.83M -392.0% |
-$1.59M +90.7% |
-$17.07M +84.5% |
-$109.91M -86.7% |
-$58.87M -178.6% |
-$21.13M -25.4% |
| Gross Profit | $45.83M -6.6% |
$49.05M -26.4% |
$66.63M +27.4% |
$52.28M +79.1% |
$29.20M +50.9% |
$19.35M |
| Shares Outstanding | 8.98M +50.3% |
5.97M +8.3% |
5.52M +186.0% |
1.93M -93.0% |
27.49M +118.5% |
12.58M -28.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2025 | $15.16M | -6.5% | +9.2% |
| Revenue (ASC 606) | December 31, 2025 | $15.16M | -6.5% | +9.2% |
| Net Income | December 31, 2025 | -$10.58M | -1443.1% | -638.6% |
| Diluted EPS | December 31, 2025 | -$1.05 | -303.8% | -1212.5% |
| Total Assets | December 31, 2025 | $122.00M | +5.0% | -2.4% |
| Cash and Equivalents | December 31, 2025 | $30.02M | +47.2% | -8.0% |
| Long-Term Debt | December 31, 2024 | $9.98M | -33.3% | -4.3% |
| Stockholders Equity | December 31, 2025 | $14.20M | -53.8% | -38.7% |
| R&D Expense | December 31, 2025 | $0.00 | -100.0% | — |
| Operating Income | December 31, 2025 | -$1.97M | -16.2% | -31.0% |
| Gross Profit | December 31, 2025 | $9.62M | -10.8% | +4.8% |
| Shares Outstanding | December 31, 2025 | 10.73M | +74.0% | +8.3% |
- AYTU BIOPHARMA, INC reported Total Revenue of $66.38 million for fiscal year 2025.
- AYTU BIOPHARMA, INC showed an increase of +1.8% in Total Revenue compared to the prior fiscal year.
- AYTU BIOPHARMA, INC reported Revenue (ASC 606) of $66.38 million for fiscal year 2025.
- AYTU BIOPHARMA, INC showed an increase of +1.8% in Revenue (ASC 606) compared to the prior fiscal year.
- AYTU BIOPHARMA, INC reported Net Income of -$13.56 million for fiscal year 2025.
- AYTU BIOPHARMA, INC showed an increase of +14.4% in Net Income compared to the prior fiscal year.
- AYTU BIOPHARMA, INC reported Diluted EPS of $5.11 per share (loss) for fiscal year 2023.
- AYTU BIOPHARMA, INC showed an increase of +93.1% in Diluted EPS compared to the prior fiscal year.
- AYTU BIOPHARMA, INC reported Total Assets of $124.18 million for fiscal year 2025.
- AYTU BIOPHARMA, INC showed an increase of +5.2% in Total Assets compared to the prior fiscal year.
- AYTU BIOPHARMA, INC reported Cash and Equivalents of $30.95 million for fiscal year 2025.
- AYTU BIOPHARMA, INC showed an increase of +54.7% in Cash and Equivalents compared to the prior fiscal year.
- AYTU BIOPHARMA, INC reported Long-Term Debt of $10.88 million for fiscal year 2024.
- AYTU BIOPHARMA, INC showed a decrease of -26.1% in Long-Term Debt compared to the prior fiscal year.
- AYTU BIOPHARMA, INC reported Stockholders Equity of $18.97 million for fiscal year 2025.
- AYTU BIOPHARMA, INC showed a decrease of -31.6% in Stockholders Equity compared to the prior fiscal year.
- AYTU BIOPHARMA, INC reported R&D Expense of $1.33 million for fiscal year 2025.
- AYTU BIOPHARMA, INC showed a decrease of -52.1% in R&D Expense compared to the prior fiscal year.
- AYTU BIOPHARMA, INC reported Operating Income of -$7.83 million for fiscal year 2025.
- AYTU BIOPHARMA, INC showed a decrease of -392.0% in Operating Income compared to the prior fiscal year.
- AYTU BIOPHARMA, INC reported Gross Profit of $45.83 million for fiscal year 2025.
- AYTU BIOPHARMA, INC showed a decrease of -6.6% in Gross Profit compared to the prior fiscal year.
- AYTU BIOPHARMA, INC reported Shares Outstanding of 8.98 million shares for fiscal year 2025.
- AYTU BIOPHARMA, INC showed an increase of +50.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: